Follow The Filings

BEAM Beam Therapeutics Inc.

Health Care, filed as BEAM THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q2, sold by 1

  • 4 Owners
  • Max 2.3%
  • $708M
  • 1 new 1 reduce 2 small

In 2026 Q2 Stanley Druckenmiller opened a position in Beam Therapeutics, while Cathie Wood trimmed.

Who owns this now

Largest portfolio weights among holders, up to 2.3% (Cathie Wood, Ark Investment Management). Not free-float ownership.

  1. Cathie Wood Reduce 2.3%
  2. Farallon Capital Management Add 1.6%
  3. Stanley Druckenmiller New 0.10%

Who owns BEAM

Sorted by value, long equity only, as of 2026 Q2.

History
Farallon Capital Management 1.6%, was 1.4% Small add +1.0% 10,236,396 $351M History
Cathie Wood, Ark Investment Management 2.3% Reduce −15.6% 10,234,862 $351M History
Stanley Druckenmiller, Duquesne Family Office 0.10% New 0.10% 153,600 $5.3M History
Murray Stahl, Horizon Kinetics Asset Management <0.01% Small trim −4.6% 8,388 $288K History

4 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BEAM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BEAM insider trades
  • None no insider bought on the open market
  • $10M sold by 1 insider outside a trading plan
  • $8.1M sold by 5 insiders under 10b5-1 plans
  1. John M. Evans CEO
    Planned sale
    $1.2M 50,000 shares at $23.77 4.6% of stake
    Traded Oct 15–16 Filed Oct 16
    ↗
  2. Amy Simon Chief Medical Officer
    Planned sale
    $429K 16,667 shares at $25.74 16% of stake
    Traded Jul 27 Filed Jul 29
    ↗
  3. John M. Evans CEO
    Planned sale
    $1.7M 50,000 shares at $34.90 4.6% of stake
    Traded Jun 29–30 Filed Jul 1
    ↗
  4. Fmr LLC 10% owner
    Sale
    $10M 284,860 shares at $35.24 25% of stake
    Traded Jun 25–26 Filed Jun 29
    ↗
  5. John M. Evans CEO
    Planned sale
    $1.1M 50,000 shares at $22.57 4.8% of stake
    Traded Mar 30–31 Filed Apr 1
    ↗
  6. Giuseppe Ciaramella President
    Planned sale
    $1.1M 35,000 shares at $32.00 16% of stake
    Traded Feb 24 Filed Feb 26
    ↗
  7. John M. Evans CEO
    Planned sale
    $1.4M 50,000 shares at $28.87 4.8% of stake
    Traded Jan 29–30 Filed Feb 2
    ↗
  8. Bethany J Cavanagh SVP, Finance and Treasurer
    Planned sale
    $217K 6,198 shares at $35.00 15% of stake
    Traded Jan 22 Filed Jan 26
    ↗
  9. Christine Bellon Chief Legal Officer
    Planned sale
    $47K 1,371 shares at $34.00 1.4% of stake
    Traded Jan 22 Filed Jan 26
    ↗
  10. Bethany J Cavanagh SVP, Finance and Treasurer
    Planned sale
    $91K 3,034 shares at $30.12 6.9% of stake
    Traded Jan 20 Filed Jan 21
    ↗
  11. Christine Bellon Chief Legal Officer
    Planned sale
    $645K 18,629 shares at $34.61 16% of stake
    Traded Jan 15 Filed Jan 20
    ↗
  12. Fmr LLC 10% owner
    Sale
    $12K 459 shares at $26.68 97% of stake
    Traded Oct 27, 2025 Filed Oct 29, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 13 option exercises, 9 sales to cover taxes, 7 stock grants, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.02 Filing Doc
8-K 1.01,2.02,2.03,9.01 Filing Doc
10-K Filing Doc

Source: SEC EDGAR submissions, updated 13 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $377.71M $63.52M $139.74M
Net income -$132.53M -$376.74M -$79.99M
Net margin * -35.1% -593.1% -57.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.21B $0.878B $1.27B
Total non-current assets * $248.67M $225.68M $212.49M
Total assets $1.46B $1.1B $1.48B
Total current liabilities $205.56M $182.07M $96.94M
Total non-current liabilities * $272.82M $188.21M $145.88M
Total equity $0.981B $0.734B $1.24B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$149.2M -$347.25M -$345.1M
Cash from investing $71.84M $185.01M -$121.44M
Cash from financing $276.45M $7.74M $478.05M
Net change in cash $199.09M -$154.5M $11.51M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.